Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive trial result, but the market price for YES is 0.4927, which seems to imply a lower market expectation. Given the portfolio has $17044.762 in cash and a max buy...
Intrinsic probability (62%) offers a meaningful edge over the current market price of 48.8%. With a confident forecast driven by strong mechanistic rationale and mature trial status, the risk-reward justifies a maximum...
Intrinsic probability (42%) is close to market price (48.8%). The mispricing is minor and insufficient to overcome the high trial uncertainty and binary event risk. No trade is justified.
Market pricing near 49% overestimates the likelihood of success for an unvalidated MOA in a notoriously difficult indication, particularly after a recent trial failure in a similar exploratory setting.
Intrinsic YES 42% < mkt 49% (NO undervalued at 51% vs 58%). 7pp edge + Ph2 vol justifies max buy $1k cap. No shorts held.
